News Sentiment

ORKA sentiment intelligence

Oruka Therapeutics, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 92.70 Week of 17 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+6.8% over one week, +28.1% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Oruka Therapeutics Inc. (ORKA) Stock Price | Live Quotes & Charts | NASDAQ

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction 6.8% Price confirming higher
Trend fit Trend active 28.1% over four weeks
Fair value 275.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 33
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 16
GlobeNewswire 6
MT Newswires 4
simplywall.st 3
BizWest 3
Quiver Quantitative 2
Investing.com 2
Stock Titan 2

Event Lens

What the news is about

Classified themes
Market update 25
Deals and strategy 13
Earnings 11
Analyst action 2
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 52
GlobeNewswire Direct company coverage

Oruka Therapeutics Announces Closing of Merger with ARCA

Oruka Therapeutics announced the completion of its merger with ARCA biopharma and a $275 million private placement. The combined company, now trading on Nasdaq under "ORKA", aims to advance pipeline programs ORKA-001 and ORKA-002 for chronic skin diseases. Dr. Samarth Kulkarni ha

Tone
Positive 72/100
Event
Deals and strategy
Published
13 May 2026 19:09
Source
GlobeNewswire
Stock Titan Direct company coverage

Oruka Therapeutics (ORKA) Stock News, Page 4

This page provides news and updates for Oruka Therapeutics (ORKA), a clinical-stage biotechnology company focused on novel biologics for chronic skin diseases. Recent news highlights preclinical data for ORKA-001 showing extended half-life, a $200 million private placement financ

Tone
Positive 61/100
Event
Market update
Published
30 Apr 2026 19:39
Source
Stock Titan